Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancer

Pathophysiological Roles of Histamine Receptors in Cancer Progression: Implications and Perspectives as Potential Molecular Targets

“…In other studies conducted in HCC cell lines, cimetidine disrupted the epidermal growth factor (EGF)-induced autophosphorylation of EGF receptors and its downstream effectors by reducing the cAMP concentration, resulting in suppression of EGF-induced proliferation and migration [170]. In agreement with these preclinical studies, clinical trials using H2R antagonists (ranitidine and cimetidine) showed significant increases in OS when they were used as an adjuvant treatment for patients undergoing curative resection of CRC [159,171] or head and neck squamous cell carcinoma [172]. Nevertheless, the administration of H2R antagonists failed to reduce tumor growth in some other cancers.…”

Pathophysiological Roles of Histamine Receptors in Cancer Progression: Implications and Perspectives as Potential Molecular Targets

“…In other studies conducted in HCC cell lines, cimetidine disrupted the epidermal growth factor (EGF)-induced autophosphorylation of EGF receptors and its downstream effectors by reducing the cAMP concentration, resulting in suppression of EGF-induced proliferation and migration [170]. In agreement with these preclinical studies, clinical trials using H2R antagonists (ranitidine and cimetidine) showed significant increases in OS when they were used as an adjuvant treatment for patients undergoing curative resection of CRC [159,171] or head and neck squamous cell carcinoma [172]. Nevertheless, the administration of H2R antagonists failed to reduce tumor growth in some other cancers.…”

Association between use of antacid medications (proton pump inhibitors and histamine-2 receptor antagonists) and the incidence of lung cancer: A population-based cohort analysis

“…[18] Furthermore, PPIs and H-2 antagonists may improve the survival of patients with various cancers, including lung cancer. [19][20][21][22][23][24] Taken together, these results suggest that antacid medications (PPIs and H-2 antagonists) may have chemopreventive potential against lung cancer. It is important to determine the chemopreventive potential of antacid medications to better inform decisions regarding the appropriate medication.…”

Repurposing non-cancer Drugs in Oncology – How many drugs are out there?

“…Several drugs have shown a survival benefit in randomized trials such as cimetidine (colorectal cancer) 13 , progesterone (breast cancer) 14 or itraconazole (lung cancer) 15 . Of note, several other drugs induced responses in rare tumours, like clarithromycin 16 , timolol 17,18 or propranolol [19][20][21][22] .…”

Pathophysiological Roles of Histamine Receptors in Cancer Progression: Implications and Perspectives as Potential Molecular Targets

“…In other studies conducted in HCC cell lines, cimetidine disrupted the epidermal growth factor (EGF)-induced autophosphorylation of EGF receptors and its downstream effectors by reducing the cAMP concentration, resulting in suppression of EGF-induced proliferation and migration [170]. In agreement with these preclinical studies, clinical trials using H2R antagonists (ranitidine and cimetidine) showed significant increases in OS when they were used as an adjuvant treatment for patients undergoing curative resection of CRC [159,171] or head and neck squamous cell carcinoma [172]. Nevertheless, the administration of H2R antagonists failed to reduce tumor growth in some other cancers.…”

Association between use of antacid medications (proton pump inhibitors and histamine-2 receptor antagonists) and the incidence of lung cancer: A population-based cohort analysis

“…[18] Furthermore, PPIs and H-2 antagonists may improve the survival of patients with various cancers, including lung cancer. [19][20][21][22][23][24] Taken together, these results suggest that antacid medications (PPIs and H-2 antagonists) may have chemopreventive potential against lung cancer. It is important to determine the chemopreventive potential of antacid medications to better inform decisions regarding the appropriate medication.…”

Repurposing non-cancer Drugs in Oncology – How many drugs are out there?

“…Several drugs have shown a survival benefit in randomized trials such as cimetidine (colorectal cancer) 13 , progesterone (breast cancer) 14 or itraconazole (lung cancer) 15 . Of note, several other drugs induced responses in rare tumours, like clarithromycin 16 , timolol 17,18 or propranolol [19][20][21][22] .…”

Pathophysiological Roles of Histamine Receptors in Cancer Progression: Implications and Perspectives as Potential Molecular Targets

“…In other studies conducted in HCC cell lines, cimetidine disrupted the epidermal growth factor (EGF)-induced autophosphorylation of EGF receptors and its downstream effectors by reducing the cAMP concentration, resulting in suppression of EGF-induced proliferation and migration [170]. In agreement with these preclinical studies, clinical trials using H2R antagonists (ranitidine and cimetidine) showed significant increases in OS when they were used as an adjuvant treatment for patients undergoing curative resection of CRC [159,171] or head and neck squamous cell carcinoma [172]. Nevertheless, the administration of H2R antagonists failed to reduce tumor growth in some other cancers.…”

Association between use of antacid medications (proton pump inhibitors and histamine-2 receptor antagonists) and the incidence of lung cancer: A population-based cohort analysis

“…[18] Furthermore, PPIs and H-2 antagonists may improve the survival of patients with various cancers, including lung cancer. [19][20][21][22][23][24] Taken together, these results suggest that antacid medications (PPIs and H-2 antagonists) may have chemopreventive potential against lung cancer. It is important to determine the chemopreventive potential of antacid medications to better inform decisions regarding the appropriate medication.…”

Repurposing non-cancer Drugs in Oncology – How many drugs are out there?

“…Several drugs have shown a survival benefit in randomized trials such as cimetidine (colorectal cancer) 13 , progesterone (breast cancer) 14 or itraconazole (lung cancer) 15 . Of note, several other drugs induced responses in rare tumours, like clarithromycin 16 , timolol 17,18 or propranolol [19][20][21][22] .…”